Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk

We aimed to compare the (1) clinical outcomes including composite cardiovascular outcomes, cardiovascular death, and all-cause death, and (2) healthcare costs of using liraglutide and basal insulin as an initial treatment for patients with type 2 diabetes mellitus (T2DM) and high cardiovascular dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wan-Chun, Chen, Yen-Chou, Wu, Chung-Hsuen, Ko, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809152/
https://www.ncbi.nlm.nih.gov/pubmed/33446845
http://dx.doi.org/10.1038/s41598-020-80753-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809152/
https://www.ncbi.nlm.nih.gov/pubmed/33446845
http://dx.doi.org/10.1038/s41598-020-80753-9

Ejemplares similares